REGISTER
Two Chinese B7-H3 ADCs Selected for WCLC 2026 Presidential Symposium
Two Chinese B7-H3 antibody-drug conjugate (ADC) phase 3 trials—TAISHAN-302 (YL201) and ARTEMIS-008 (HS-20093)—have been selected for the 2026 World Conference on Lung Cancer (WCLC) Presidential Symposium. Both evaluate the respective ADC versus topotecan in relapsed small cell lung cancer (SCLC), with overall survival as the primary endpoint. Early-phase data showed ORR of 63.9% (YL201) and 52.3% (HS-20093), with treatment-related ILD rates of 1.3% and 3.4%.

Small cell lung cancer (SCLC) is highly aggressive, with a tendency for relapse and metastasis. After first-line resistance, effective second-line and later-line treatment options remain limited, and the field has an unmet need for new therapeutic approaches. B7-H3 (CD276) is widely overexpressed in SCLC and other malignancies and has emerged as a target of interest in antibody-drug conjugate (ADC) development.

Two Chinese B7-H3 Studies Selected for WCLC Presidential Symposium

According to the article, among 8 global studies selected for the Presidential Symposium of the upcoming 2026 World Conference on Lung Cancer (WCLC), 2 are led by Chinese teams. Both are phase 3 trials in relapsed SCLC, comparing the respective ADC with the second-line standard topotecan, with overall survival (OS) as the primary endpoint:

- Prof. Li Zhang of Sun Yat-sen University Cancer Center will present the TAISHAN-302 study (Abstract PL02.03) of YL201 (Tam-Peli), developed by YL Pharma.

Fig. 1. Prof. Li Zhang’s Team Presenting the Study

- Prof. Jie Wang of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, will present the ARTEMIS-008 study (Abstract PL02.04) of HS-20093 (Ris-Rez), developed by Hansoh Pharma.

Fig. 2. Prof. Jie Wang’s Team Presenting the Study

The simultaneous presentation of these two phase 3 trials is expected to provide evidence for evaluating the confirmatory clinical value of B7-H3 ADCs in SCLC.

Early-Phase Data Review

The article reviews early-phase data for both ADCs that have been previously published.

YL201 (Tam-Peli) Phase I/Ib Study (Published in Nature Medicine)

In the evaluable extensive-stage SCLC (ES-SCLC) cohort:

- Confirmed objective response rate (cORR): 63.9%

- Disease control rate (DCR): 91.7%

- Median duration of response (mDOR): 5.7 months

- Median progression-free survival (mPFS): 6.3 months

Adverse events were primarily hematologic toxicities, with common grade ≥3 treatment-related adverse events (TRAEs) including neutropenia, leukopenia, and anemia. Treatment-related interstitial lung disease (ILD) occurred in 1.3% of patients.

HS-20093 (Ris-Rez) Phase I ARTEMIS-001 Study (Published in Cancer Cell)

In 65 evaluable ES-SCLC patients (approximately 60% had received ≥2 prior lines of therapy):

- Confirmed ORR: 52.3%

- DCR: 87.7%

- mDOR: 7.1 months

- mPFS: 6.2 months

The most common grade ≥3 TRAEs were also hematologic toxicities (decreased neutrophil count, decreased white blood cell count, and anemia). Treatment-related ILD occurred in 3.4% of patients.

According to the article, both ADCs showed high tumor response rates and response durations in the later-line SCLC population in early studies, providing a clinical basis for the subsequent phase 3 randomized studies.

Conference Focus: Key Points to Watch in the Phase 3 Studies

ARTEMIS-008 announced in July 2026 that it met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningful improvement in OS with Ris-Rez compared with topotecan. TAISHAN-302 will present full data at this year’s meeting.

As complete data are presented, several metrics warrant attention:

- Long-term survival benefit: whether the high response rates translate into meaningful survival extension, and whether improvements in progression-free survival (PFS), duration of response (DOR), and final OS are consistent.

- Clinical safety: the hematologic toxicity profile, dose reduction rates, discontinuation rates, and ILD incidence, which directly affect whether the drug can be administered long-term in real-world clinical practice.

- Performance in difficult-to-treat subgroups: whether the two ADCs provide benefit in patients who have previously received first-line immunotherapy, those with primary platinum resistance, and those with baseline brain metastases.

Summary

The inclusion of two Chinese phase 3 trials in the WCLC 2026 Presidential Symposium reflects the contributions of Chinese researchers to relapsed SCLC research. The full OS data from TAISHAN-302 and ARTEMIS-008 are expected to provide key evidence on whether B7-H3 ADCs have the potential to change clinical practice in relapsed SCLC.

This article is based on a pre-conference press release; the full phase 3 data have not yet been publicly presented. ARTEMIS-008 has announced meeting its primary endpoint, but detailed results will be presented at WCLC 2026. TAISHAN-302 and ARTEMIS-008 early-phase results have been published in Nature Medicine and Cancer Cell, respectively.

0
0
Loading